Results 71 to 80 of about 5,496,645 (302)

Guidelines for diagnosis and treatment of advanced breast cancer in China (2022 edition)

open access: yesJournal of the National Cancer Center
Breast cancer is the most common cancer among women worldwide. It has been estimated that about 416 000 new cases and over 117 000 deaths of breast cancer occurred in China in 2020.
doaj   +1 more source

Polymorphisms of the receptor for advanced glycation end products and glyoxalase I and long-term outcome in patients with breast cancer

open access: yesTumor Biology, 2017
Receptor for advanced glycation end products and glyoxalase I metabolizing advanced glycation end product precursors may play important role in the pathogenesis and progression of cancer.
Petra Tesarova   +3 more
doaj   +1 more source

Burden of early, advanced and metastatic breast cancer in The Netherlands

open access: yesBMC Cancer, 2018
Background The aim of this study was to estimate the total economic and health related burden of breast cancer in the Netherlands. Methods Data on incidence, prevalence, mortality and survival were extracted from the Dutch National Cancer Registry and ...
G. T. Vondeling   +6 more
doaj   +1 more source

Candidate circulating microRNAs as potential diagnostic and predictive biomarkers for the monitoring of locally advanced breast cancer patients

open access: yesTumor Biology, 2020
This study aimed at investigating the expression of candidate microRNAs (miRs), at initial diagnosis, during neoadjuvant chemotherapy, and after the tumor resection in locally advanced breast cancer patients.
Alaa M Ibrahim   +4 more
doaj   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

open access: yesMolecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim   +3 more
wiley   +1 more source

Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls. [PDF]

open access: yes, 2010
BACKGROUND: Truncating mutations in ATM have been shown to increase the risk of breast cancer but the effect of missense variants remains contentious.
Schürmann, Peter   +425 more
core   +1 more source

Glutamine Metabolism Drives Growth in Advanced Hormone Receptor Positive Breast Cancer

open access: yesFrontiers in Oncology, 2019
Dependence on the glutamine pathway is increased in advanced breast cancer cell models and tumors regardless of hormone receptor status or function. While 70% of breast cancers are estrogen receptor positive (ER+) and depend on estrogen signaling for ...
Diane M. Demas   +8 more
doaj   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

open access: yesMolecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington   +10 more
wiley   +1 more source

Ausencia de la mutación BRCA1 del (exones 9-12) en familias con cáncer de seno / ovario fuera de hispanos mexicanos [PDF]

open access: yes, 2009
3 páginasThe frequency and spectrum of germ line mutations in the high-penetrance breast cancer susceptibility genes BRCA1 and BRCA2 shows considerable variation by ethnic group.
Seidel Renkert, Antje   +8 more
core   +1 more source

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

open access: yesMolecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy